Mersana Therapeutics ( (MRSN) ) has shared an update.
On March 3, 2025, Mersana Therapeutics announced positive initial Phase 1 clinical data for its lead ADC candidate, Emi-Le, and received a second Fast Track designation from the FDA. The company also initiated an expansion cohort for patients with triple-negative breast cancer and plans to present further clinical data in 2025. Financial results for 2024 showed a net loss reduction compared to 2023, with increased collaboration revenue and decreased R&D and G&A expenses due to restructuring and discontinued projects.
More about Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) to address high unmet medical needs in cancer treatment. The company utilizes proprietary platforms, Dolasynthen and Immunosynthen, to create a pipeline of product candidates, including Emi-Le and XMT-2056, targeting specific cancer markers.
YTD Price Performance: -62.64%
Average Trading Volume: 5,369,586
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $64.66M
Learn more about MRSN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com